Isabella Tilmont earned a BS in Neuroscience with a double minor in Chemistry and Leadership Studies from Christopher Newport University (Newport News, VA) and an MS in Biochemistry and Molecular & Cellular Biology from Georgetown University with an emphasis on cancer biology (Washington, DC). Her graduate research aim was to determine lipid peroxidation in ER+ breast cancer cells that are sensitive or resistant to endocrine therapy following ROS-induced ferroptosis, and she worked to establish, optimize, and troubleshoot protocols to measure peroxidized lipids using specific antibodies through western blotting. Following graduation, she worked in a clinical immunology lab supporting COVID-19 vaccine efforts (optimization and clinical trial testing) through Operation Warp Speed at Novavax, Inc. (Gaithersburg, MD). She then joined AstraZeneca, where she is now a Senior Scientist supporting a Ph3 clinical antibody drug conjugate asset in ovarian and lung indications. Her work has contributed to the program's success and enabled lines of sight in tertiary indications to help deliver new medicines to patients in need. She is a member of Chi Alpha Sigma, Nu Rho Psi, Alpha Chi, and Alpha Chi Sigma - Delta Zeta. Her present interests include translational medicine, novel drug discovery and delivery, oncology strategy, and asset management.
Isabella Tilmont earned a BS in Neuroscience with a double minor in Chemistry and Leadership Studies from Christopher Newport University (Newport News, VA) and an MS in Biochemistry and Molecular & Cellular Biology from Georgetown University with an emphasis on cancer biology (Washington, DC). Her graduate research aim was to determine lipid peroxidation in ER+ breast cancer cells that are sensitive or resistant to endocrine therapy following ROS-induced ferroptosis, and she worked to establish, optimize, and troubleshoot protocols to measure peroxidized lipids using specific antibodies through western blotting. Following graduation, she worked in a clinical immunology lab supporting COVID-19 vaccine efforts (optimization and clinical trial testing) through Operation Warp Speed at Novavax, Inc. (Gaithersburg, MD). She then joined AstraZeneca, where she is now a Senior Scientist supporting a Ph3 clinical antibody drug conjugate asset in ovarian and lung indications. Her work has contributed to the program's success and enabled lines of sight in tertiary indications to help deliver new medicines to patients in need. She is a member of Chi Alpha Sigma, Nu Rho Psi, Alpha Chi, and Alpha Chi Sigma - Delta Zeta. Her present interests include translational medicine, novel drug discovery and delivery, oncology strategy, and asset management.